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Abstract 
 In 2004, a database was implemented to assess the treatment of inmates infected 
with hepatitis C in Massachusetts state correctional facilities.  The purpose of this project 
was to update the database and examine the current treatment system.  Inmate 
demographics, treatment success, and viral characteristics were assessed and analyzed for 
potential correlations.  Recommendations to improve the database included focusing on 
the collection of missing data, namely the inmate’s history of substance abuse and health 
conditions and follow up viral load measures. 
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What is Hepatitis C? 
  
 By definition, hepatitis is an “inflammation of the liver” (Merriam-Webster 
Incorporated, 2006).  It is a gastroenterological disease that results in damage to the liver 
cells, and depending on the severity, may even destroy them.  There are a number of 
different types of hepatitis which can be caused by a variety of factors including other 
illnesses or diseases, noninfectious substances such as drugs, alcohol, or toxic chemicals, 
and infectious agents such as viruses or parasites (Encyclopedia Britannica, Inc., 2007).  
In the most common cases, hepatitis is the result of a viral infection.   
 Hepatitis C is one of six currently identified types of viral hepatitis (A, B, C, D, E, 
and G).  It has become a major health concern in the United States, today, is one of the 
leading causes of liver disease, and a major reason for liver transplants (Jetter, 2005).  
True to its name, hepatitis C is a blood borne disease of the liver caused by the hepatitis 
C virus (HCV), a single-stranded RNA virus of the family Flaviviridae.  HCV can be 
categorized into six major genotypes and more than 50 subtypes.  Genotypes range in 
geographic distribution and response to treatment, but show little difference in the 
severity of the disease or outcome.  The most common genotypes in the US are 1a and 
1b, which account for over 70% of the cases (National Digestive Diseases Information 
Clearinghouse [NDDIC], 2006).   
 Characteristic of a blood borne infection, HCV is carried through the blood and 
transmitted primarily via contact with infected blood and blood products (NDDIC, 2006).  
Major risk factors associated with the transmission of HCV include blood transfusions 
and transplants, injection or use of illegal drugs, occupational exposure (i.e. healthcare 
workers), high risk sexual behavior with an infected partner, and non-sterile instrument 
use for tattoos or body piercing (Centers for Disease Control and Prevention [CDC], 
1998).  HCV may not be transmitted through casual contact with an infected person and 
is rarely acquired through maternal-infant transmission or household contact with 
infected blood or fluids.  At present, injection drug use is the most common form of HCV 
transmission in the United States (NDDIC, 2006).  
Types and Symptoms 
 Hepatitis C is typically categorized into one of two stages: acute hepatitis C or 
chronic hepatitis C.  Each stage refers to the current progression of the viral infection and 
depends upon the length of infection time and the severity of the disease.  In either case, 
HCV poses a potential number of dangers to the liver.   
 Acute hepatitis C is used to describe the first six months of infection, during 
which the liver is first attacked by HCV, liver inflammation initiates, and liver enzyme 
levels begin to rise.  Persons with acute infections are usually asymptomatic and unaware 
of the virus they are carrying.  Those who do develop symptoms exhibit mild, non-
specific flu-like signs such as fatigue, sore muscles, headaches, nausea, and loss of 
appetite, and in some cases, may also acquire jaundice (Jetter, 2005).  These symptoms 
usually do not develop until 6-7 weeks after infection and are often mistaken for other 
medical conditions or disappear before raising any serious concern.  According to studies 
and organizations such as the National Institute of Diabetes and Digestive and Kidney 
Diseases, between 75% and 85% of those with acute hepatitis C will eventually progress 
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into a more severe, long-term chronic form of hepatitis C due to a lack of treatment or 
failure to respond to treatment within the first six months (CDC, 1998). 
 Chronic hepatitis C is defined as an HCV infection that has progressed beyond six 
months.  It the most commonly diagnosed form of hepatitis C and is a major cause of 
cirrhosis, liver failure, and liver cancer (Liang, Rehermann, Seef, & Hoofnagle, 2000).  
Depending upon the severity of the infection, chronic hepatitis C varies greatly among 
patients in its course and outcome.  For instance, those with mild chronic hepatitis C 
typically have no signs or symptoms of liver disease and exhibit rather minor damage to 
the liver.  On the other hand, those patients with severe chronic hepatitis C demonstrate 
high levels of HCV virus in the blood, elevated liver enzyme levels (indicating liver 
disease), severe physical damage to the liver, and more specific symptoms such as 
muscle weakness, weight loss, itching, dark urine, fluid retention, and abdominal 
swelling.  The majority of these patients will ultimately develop cirrhosis and end-stage 
liver disease.  For the many patients who fall in the middle of the spectrum, chronic HCV 
infection is characterized by mild to moderate elevations in liver enzymes and few or no 
symptoms.  In 1-2% of patients, chronic hepatitis C can cause complications outside the 
liver known as extrahepatic manifestations.  These may include such conditions as 
cyroglobulinemia, glomerulonephritis, and porphyria cutanea tarda (NDDIC, 2006).      
 Despite the potential dangers of HCV infection, hepatitis C lies dormant in most 
patients for years.  Statistics have shown that as many as 70% of those infected with 
HCV are unaware of the virus and more than half show no signs or symptoms of HCV 
infection.  (Jetter, 2005; Henkel, 1999)  In fact, hepatitis C is frequently not recognized 
until infected individuals undergo blood-donor screenings that are positive for HCV or 
routine physical exams that show elevated liver enzyme levels (CDC, 1998). 
Testing and Diagnosis  
 Persons suspected to have an HCV infection must undergo a number of blood 
tests before they can be diagnosed with hepatitis C.  Blood tests range in specificity and 
are designed to test for indicators of an HCV infection, HCV antibodies, and the HCV 
virus itself.    
 One of the most frequent indicators of a potential HCV infection is elevated levels 
of liver enzymes, or more specifically, alanine aminotransferase (ALT).  Most people 
infected with HCV exhibit elevated levels of liver enzymes, such as ALT, on a routine 
blood test within 50 days of exposure (Jetter, 2005).  Although not all infected patients 
show signs of alteration in their ALT levels, persistently abnormal levels of ALT are fair 
indicators that an infection may be present and that further tests should be conducted.   
ALT tests are not designed to confirm HCV infection, but are rather a nonspecific means 
of initially screening for infection (Herrine, 2002).   
 To determine whether or not an HCV infection is actually present, individuals are 
screened for the presence of HCV antibodies (anti-HCV) using a series of U.S. Food and 
Drug Administration (FDA) approved diagnostic tests (CDC, 1998).  Anti-HCV is 
usually present in the blood of infected individuals within one month of exposure to the 
virus (NDDIC, 2006).  If hepatitis C is suspected based on symptoms and/or ALT levels, 
an enzyme immunoassay (EIA) is first conducted and then later confirmed by a 
supplementary recombinant immunoblot assay (RIBA), a western blot specific for anti-
HCV.  Two positive results indicate an HCV infection, while two negative results 
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indicate no infection.  Indeterminate results are usually indicative of a recently infected 
person, a person with chronic HCV, or poor testing.  Anti-HCV test results do not 
characterize the type of hepatitis C or distinguish between patients with an acute, chronic, 
or recently treated infection (CDC, 1998).     
 In most patients, hepatitis C viral RNA can be detected within one to two weeks 
of HCV infection, long before the presence of anti-HCV or elevated ALT levels (CDC, 
1998).  As further confirmation of an active HCV infection, qualitative and quantitative 
assays can be done to detect the presence or absence of HCV RNA.  Qualitative assays, 
such as the polymerase chain reaction (PCR) and transcription-mediated amplification 
(TMA) are usually done to determine whether or not HCV RNA is present in the serum.  
Quantitative assays, on the other hand, are conducted as indirect assessments of the 
amount of HCV RNA present in the blood.  These viral loads determined by assays such 
as quantitative RT-PCR and branched DNA signal amplification do not directly correlate 
with the severity of hepatitis C, but are a good indication of the likelihood of a response 
to antiviral therapy (NDDIC, 2006). 
In the majority of cases, elevated ALT levels and the presence of anti-HCV in the 
blood serum is enough to diagnose an individual with hepatitis C.  Additional testing is 
typically done to either confirm the diagnosis or characterize the infection in preparation 
for treatment.  Genotyping and liver biopsies are common examples of characterization 
tests performed to determine the genotype of the hepatitis C virus and the severity of the 
infection, respectively.  Tests, like these, are good indicators of how a patient will 
respond to different treatments and which treatment will work best (NDDIC, 2006).  
Some states have also found these tests, particularly the liver biopsy, to be cost effective. 
In 2004, the Virginia Department of Corrections offered all inmates who tested positive 
for HCV RNA the opportunity to get a liver biopsy.  This approach allowed physicians to 
avoid unnecessary treatment by treating only those inmates in the advanced state of the 
disease.  It was estimated that liver biopsies saved almost $125,000 per 100 patients 
(Sterling, 2003).    
Treatment  
 Presently, there is no cure or vaccine for hepatitis C.  Like most viruses that cause 
chronic conditions, HCV RNA mutates very rapidly inside the human body.  HCV 
infection elicits some response from the immune system early on, but constant mutations 
essentially allow the virus to evade the immune system over time and inhibit the 
development of preventative drugs (NDDIC, 2006).  Consequently, the only options 
available for patients today are moderately successful treatments aimed at the elimination 
of detectable virus in the blood serum.  Success of treatment is usually measured in terms 
of sustained virologic response, which can be defined as “the absence of HCV RNA in 
the serum during therapy and six months after completion of therapy” (Herrine, 2002). 
 Effective treatment for hepatitis C first began over 10 years ago, when alpha 
interferon was approved for treatment of non-A and non-B hepatitis in 1991 (Herrine, 
2002).  Treatment required that the antiviral protein be injected subcutaneously at least 
three times a week for approximately 12 months.  Initial results indicated normalized 
ALT levels and a loss of detectable HCV RNA in the serum of most patients by the end 
of the therapy.  However, long term studies of treatment with alpha interferon have 
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demonstrated a high relapse rate among patients and sustained viral response rates of 
only 15%-25% (CDC, 1998). 
 Current treatment therapies have replaced alpha interferon with pegylated 
interferon (peginterferon), a more successful recombinant form of the original protein.  
Chemical modification of alpha interferon by the addition of polyethylene glycol has 
improved the uptake, distribution, and excretion of interferon, and increased active 
inhibition of HCV.  Like alpha interferon, peginterferon must be injected subcutaneously.  
Chemical improvements, however, have reduced the treatment requirements from 
injections three times a week to only once a week for approximately 48 weeks.  Studies 
have shown an overall increase in sustained viral response rates with peginterferon 
monotherapy to approximately 35% (NDDIC, 2006).    
 In 1998, hepatitis C treatment was further enhanced when the FDA approved the 
combination of interferon and ribavirin as treatment for patients with chronic hepatitis C 
(Herrine, 2002).  Ribavirin is an antiviral agent that is usually taken orally two times a 
day.  It has little effect on HCV by itself, but in combination with interferon, can lower 
relapse rates, increase sustained viral response rates to as high as 55%, and has been 
shown to rapidly lower ALT levels and eliminate detectable HCV RNA in up to 70% of 
patients (NDDIC, 2006).  Combination therapy, as it is most often referred to, has 
become today’s standard form of hepatitis C treatment.  Unless specific factors prevent 
the use of ribavirin, combination therapy will be applied over interferon monotherapy in 
all present cases (Ward and Kugelmas, 2005). 
 Despite the advances made over the past decade, problems continue to hinder the 
success of hepatitis C treatment.  One of the biggest problems facing patients today is 
cost.  On average, treatment costs approximately $20,000-$30,000 per year for the 
medication alone (Ward and Kugelmas, 2005).  Although treatment is necessary for the 
management of hepatitis C in most cases, the expense of therapy often prevents 
individuals from pursing treatment.  For those who receive treatment, medication poses 
the potential for side effects that can result in reduced medication dosages or an overall 
discontinuation of treatment.   Common side effects of alpha and pegylated interferon 
include fatigue, muscle aches, headaches, depression, mild bone marrow suppression, and 
other related problems.  Side effects range from mild to moderate in severity and usually 
diminish following the first few weeks of treatment.  Common side effects of ribavirin, 
on the other hand, include anemia, fatigue, irritability, itching, birth defects, nasal 
stuffiness, sinusitis, and cough.  Ribavirin is not advised for women who are pregnant or 
likely to become pregnant or for patients with blood related problems.  Less than 2% of 
patients exhibit side effects uncharacteristic of interferon or ribavirin (NDDIC, 2006).   
 Because of the problems associated with hepatitis C therapy, treatment is not 
recommended for all patients.  In fact, treatment is only highly recommended for chronic 
hepatitis C patients who have persistently elevated ALT levels, detectable HCV RNA, 
and a liver biopsy indicating severe inflammation or damage to the liver.  These patients 
are considered to be at a greater risk for progression, and consequently, require treatment 
in order to survive.  All other patients, including those with persistently normal ALT 
levels, advanced cirrhosis, alcohol or drug abuse problems, or contraindications such as 
depression, hyperthyroidism, life-threatening complications, or evidence of pregnancy, 
are not recommended for treatment and must receive medical clearance before beginning 
any such therapy (CDC, 1998).   
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 Epidemiology 
In 2000, the United States Surgeon General declared hepatitis C a “silent 
epidemic.” With approximately 2% of the U.S. adult population infected, this appropriate 
declaration stems from the fact that hepatitis C is the most common chronic blood borne 
infection in the United States (Kim, 2002). Many of these infections will go undetected 
for years because victims display little to no symptoms during the early onset stages of 
the disease (CDC, 1998). Disease progression varies amongst individuals and depends on 
factors such as co-infection with other diseases, age, and alcohol/substance abuse 
patterns. Of those infected with the virus, up to 80% will develop chronic hepatitis and as 
much as 20% will progress into cirrhosis of the liver (Munoz-Plaza, et al., 2005). 
 Since the hepatitis C virus was only identified in the early 1990’s, accurate and 
reliable estimates of HCV infections and mortality rates in the United States are limited. 
Also, many patients with acute hepatitis are asymptomatic and, therefore, are never 
diagnosed. Additionally, some infected individuals may not have access to medical care, 
a factor which also contributes to the under-reporting of hepatitis C infection. These 
challenges make it very difficult to assess the true incidence of infection (Munoz-Plaza, 
et al., 2005). 
 As the identification and awareness of hepatitis C has led to an expanding 
movement of education, means of prevention, and enhanced testing efforts among 
injection drug users and blood donors, it is safe to predict that the incidence of HCV 
infection should begin to decline.  In fact, the number of people with transfusion-
associated HCV infection has already decreased significantly after the 1985 guidelines 
for selecting safer blood donors was implemented. Similarly, an effective system for 
screening blood for hepatitis C via HCV antibodies began in 1989, a step forward in the 
prevention of this epidemic. Moreover, the occurrence of safer needle-using practices 
among injection drug users has increased due to HIV and HCV awareness programs 
(Kim, 2002). 
 Unfortunately, the decrease in incidence of infection is not necessarily correlated 
with a decrease in the frequency of individuals infected with the virus. In fact, it is 
predicted that the prevalence of hepatitis C will increase over the years.  This is due to the 
fact that many people who have already been infected are asymptomatic and have not yet 
been reported.  There is often a significant lag time between the time of infection and the 
symptomatic manifestation of liver disease.  In fact, some people will not develop 
symptoms for up to 20 years or more.  As a result of this duration, the Center for Disease 
Control and Prevention predicts a four fold increase in the number of people reported to 
be chronically infected between 1990 and 2015 (Kim, 2002). 
 Similar to the underestimations of HCV infections, the mortality projections due 
to HCV are undoubtedly misrepresented.  Most deaths caused from hepatitis C infection 
are due to liver failure and chronic liver disease.  However, mortality statistics are based 
on the “underlying cause of death”.  Therefore, in many cases, the U.S. system of death 
designation will list liver failure rather than hepatitis C as cause of death, even if the liver 
failure was caused by hepatitis C.  In an attempt to estimate the number of deaths 
attributed to hepatitis C, the amount of in-hospital deaths from liver disease related to 
HCV was reviewed from the Healthcare Utilization Project database.  In 1998, 
approximately 4,500 people died in hospitals in the U.S. from HCV-related liver disease 
(CDC, 2007). 
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 The largest range of recorded data was used in the third National Health and 
Nutrition Examination Survey (NHANES) to estimate the overall prevalence of HCV in 
the United States. In this survey, 21,000 non-institutionalized citizens were tested for 
HCV antibodies as well as viral HCV RNA in serum. Percentages from of this pool of 
data were collected and projected onto the United States population.   According to the 
results of the NHANES, 3.9 million U.S. civilians were infected with HCV and 2.7 
million of those infected suffered from chronic infection.  Demographic disparities in the 
results indicated that infection was more prevalent in the age range of 30 to 49 years old:  
men were 20% more likely to be infected than women. The disease was most common in 
non-Hispanic blacks and least common in non-Hispanic whites.  Only 1.5% of non-
Hispanic whites had HCV whereas 3.2% of non-Hispanic blacks had HCV (Kim, 2002).  
Studies also suggest that individuals who suffer from severe mental illness are at a 
substantially higher risk for contracting blood-borne diseases such as HCV. For example, 
a particular study which focused on the occurrence of HCV among psychiatric patients 
had found that up to 19.6% of the 931 patients tested positive for HCV; this incidence 
rate is about 11 times higher than that of the rate of the normal adult population 
(Rosenberg, et al., 2001). This pattern of infection among psychiatric patients is most 
likely due to the high occurrence of drug use among the depressed and mentally ill 
populations.  
 Because syringe sharing and injection drug use is the major cause of HCV 
transmission and infection, the prevalence of HCV infection is extremely high among 
injection drug users.  Several seroprevalence studies have shown that HCV infection 
occurs in up to 90% of injection drug users (Patrick, Buxton, Bigham & Mathias, 2000). 
When users were tested in some methadone maintenance treatment centers, as much as 
96% were seropositive for HCV antibody while 62% were positive for HCV RNA 
(McCarthy & Flynn, 2001).  
HCV in Correctional Facilities 
 About 85% of HCV infected inmates who were entering a Massachusetts prison 
reported a history of hepatitis, needle-sharing and previous drug use. Research studies 
have found that many inmates either begin or continue to engage in injection drug use 
during incarceration (Munoz-Plaza, et al., 2005). Since syringes tend to be more 
frequently used by many inmates in prison, the risk for sharing needles and needle 
syringe contamination is much higher than the outside world (Muller et al., 1995). As a 
result, HCV infection is relatively elevated among correctional populations.  
 Because injection drug users represent a dominant subpopulation in correctional 
facilities, a large percentage of HCV infected persons will inhabit or pass through 
prisons. According to surveys from the Bureau of Justice Statistics, the average length of 
a prison stay is approximately two-three years. One of the most recent in-depth studies 
was performed in 1997. It was deduced that between 29% and 43% of HCV infected 
people in the U.S. are released from a correctional facility in a given year (Hammett, 
Harmon & Rhodes, 2002). Since limited factual data is available on HCV infections, an 
indirect method was used to produce a rough estimate of HCV infection in prison 
populations. The logic of this study used the CDC’s estimate of 72% to 86% of injection 
drug users are infected with HCV. The estimate of 24% of prison inmates with history of 
injection drug use was multiplied by 72% and 86% to yield an approximation that 17% to 
 6
21% of prison inmates are infected with HCV (Munoz-Plaza, et al., 2005). Furthermore, 
in 1997, a statistical analysis of this study produced an estimation of 1.3 to 1.9 million 
releases from prison had HCV; this implies that 29% to 43% of people with HCV 
infection have passed through a correctional facility in one year (Hammett, Harmon & 
Rhodes, 2002). 
 Despite the fact that such a large proportion of Americans with hepatitis C pass 
through a correctional facility, there is no national data on HCV incidence among 
inmates. Similarly, there is scarcely any data associating risk behaviors in prison with 
HCV contraction. This deficit in factual and statistical information contributes to the 
absence of a standardized system of health care and treatment programs in correctional 
settings. The collection of more data in prisons nationwide would allow for the better 
understanding of hepatitis C prevalence as well as the effectiveness of treatment; this 
would also help alleviate the controversies and challenges which have stood in the way of 
establishing national guidelines and recommendations for the management of this 
epidemic. Perhaps the establishment of a central database such as those used for cancer 
and HIV registries would enhance the progress of HCV intervention strategies (Allen, 
2003).  
 Because of the growing frequency of HCV infections among incarcerated 
populations, the National Institute of Health (NIH) and the Center for Disease Control 
and Prevention have recognized the importance of improving HCV interventions in 
correctional facilities. Specifically, the 2002 NIH consensus statement supported a more 
aggressive approach to treatment compared with the 1997 statement (Hammett, 2003). It 
has seemed to become apparent to these organizations that the period of incarceration 
provides a window of opportunity to diagnose, evaluate and treat those at risk for severe 
health problems caused by hepatitis C. At the least, the development of a systemic 
screening program would identify those infected and those at risk in an attempt to reduce 
contraction during incarceration (Allen, 2003). 
 The prospect for the establishment of prevention, education and treatment 
programs in prisons does seem ideal considering that such a large percentage of people 
infected with HCV are in a confined setting. As a majority of inmates are only 
temporarily imprisoned and serve an average sentence of two to three years, healthcare 
addressing HCV would not only benefit the health of the inmates but the safety and 
health of the friends, families and communities to which the released prisoners return.  
Additionally, prison administrators and authorities are legally obligated to administer a 
satisfactory degree of healthcare, which treatment programs could potentially provide.  A 
lack of interventions may leave prisons susceptible to lawsuits and criticism for 
neglecting the welfare of their inmates as well as the communities to which a majority of 
them are returned.  For example, lawsuits have taken place in New Jersey when prisoners 
became aware of HCV programs in Pennsylvania prisons which dwarfed the comparable 
programs available in New Jersey facilities (Hammett, 2003). 
As this issue remains a fairly new one, only a handful of prison systems have 
incorporated an HCV intervention program into their health management systems; among 
them are the Federal Bureau of Prisons, and facilities in Pennsylvania, Rhode Island, 
Wisconsin, Massachusetts and Indiana. (Hammett, 2003). 
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Management Strategies for Correctional Settings 
 There are many components involved in the establishment of an efficient and 
productive HCV treatment system in correctional facilities. The level of staff 
involvement, medical resources, and funding allotted for the development of an HCV 
management program usually varies between state correctional systems. As a result, there 
exists a range of protocols and tactics implemented by different correctional facilities in 
addressing this prevalent disease. Nevertheless, HCV management systems in 
correctional facilities will employ comparable strategies as well as encounter similar 
challenges.  
Prevention and Education 
A major component involving the management and containment of this disease 
involves methods of prevention.  Because there is no vaccine for HCV, preventative 
tactics must rely on education and risk-reduction practices. Health education can take the 
form of workshops, class presentations, videos, posters and brochures.  Information 
dispersed covers risk factors for infection, methods of prevention such as clean needle 
use and routes of transmission.  For example, a grassroots organization in Oregon 
conducts educational workshops for prisoners throughout the state (Munoz-Plaza, et al., 
2005).  Other prisons have utilized a peer education program in which professionals train 
inmates on how to provide counseling and education to fellow inmates.  These peer 
educators have several advantages including the fact that they are much more accessible 
for private discussions than prison authorities and staff. Also, peers provide a more 
trustworthy, credible and comfortable source of consultation.  Prisoners have admitted 
that they rarely listen to staff, but they will take advice from other inmates much more 
seriously.  Furthermore, prisoners have reported that they fear appearing like a “snitch” if 
they are seen while engaged in a private discussion with a staff member (Munoz-Plaza, et 
al., 2005). 
 In an Australian journal article, other more extreme measures of prevention have 
been suggested to combat the HCV epidemic in the Australian prison system. One 
approach to limit HCV incidence is to provide methadone maintenance treatments for 
prisoners. Methadone substitution should help opiate-dependent injectors to decrease 
injecting usage. Another suggestion is for prison authorities to enforce lesser punishments 
for the use of non-injectable drugs compared with injectable drugs. This should 
encourage drug-dependent prisoners to try alternative drug methods which should 
decrease the usage of needle use amongst inmates (Dolan, 2001). Moreover, a third major 
strategy would be to make sterile injection resources more available, provide 
disinfectants to clean needles, and/or to implement sanitary needle/exchange programs.  
However, this remains to be a controversial topic as authorities do not want to condone 
drug usage (Vlahov, Astemborski, Solomon & Nelson, 1994). It is also believed that 
transmission of HCV in prisons is due to unsanitary tattooing practices. An approach to 
limit HCV infection would be to properly train selected inmates on the sterile and proper 
techniques of tattooing as well as provide autoclaves and single-use ampoules of ink 
(Dolan, 2001). 
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Screening  
Aside from the educational and preventative measures taken by some correctional 
facilities, a major initial step in an HCV management program is screening individuals 
for infection. Recent guidelines from the Center for Disease Control indicate that all 
inmates should be questioned for risk factors regarding HCV infection during their entry 
medical evaluation.  Those inmates who affirm to any of those risk factors should be 
tested for HCV. 
 Both universal and targeted screening approaches have been practiced in different 
prison systems. In Indiana, mandatory testing for HCV and HIV has been enforced. The 
Indiana Department of Health oversees the testing procedures in which each inmate must 
donate blood samples. The system in Wisconsin practices a targeted screening approach 
in which select individuals require testing if their answers to risk-based assessments 
imply risk. Some of the many risks listed in the survey included a history of needle 
sharing, being a recipient of blood clotting factor before 1987, being on long-term 
hemodialysis, having been infected with hepatitis B, and having evidence of liver disease 
(Allen, 2003). 
 Although a systematic approach for antiviral treatment is available, the HCV 
management system in Rhode Island correctional facilities has a weakness in its 
screening methods. They lack any form of routine screening despite the high percentage 
(~26%) of inmates who are infected at any given time. As screening is not mandatory or 
routine, inmates in Rhode Island must individually request to be tested (Hammett, 2003). 
Mental Illness and Substance Abuse 
The correctional population has a high percentage of inmates with psychiatric 
illness and/or histories of substance abuse. These two groups used to be excluded from 
any type of HCV treatment. However, several findings have allowed the NIH consensus 
statement in 2002 to lift the standard contraindication for therapy for those with 
substance abuse problems. Experts believe that a correctional setting can be an ideal 
place for treatment since sobriety is heavily enforced. As long as substance abuse 
counseling is readily available and inmates are monitored closely while on treatment, 
substance abuse is no longer an accepted contraindication for HCV treatment. Similarly, 
having psychiatric illness will no longer exclude a prisoner from treatment. Because 
interferon will chemically lower the body’s amount of tryptophan, which is a precursor of 
serotonin, it was originally believed that treating a mentally ill patient with interferon 
would dangerously exacerbate his/her psychiatric state. Currently, several studies have 
shown no evidence supporting the assumption that treatment will cause more severe 
depression in those already afflicted with mental health disorders. In addition, the close 
clinical monitoring which can be provided in prison may provide a safer clinical setting 
for treatment for mentally ill inmates. However, the eligibility criteria for receiving 
treatment will ultimately be decided by each correctional setting (Allen, 2003). 
Challenges 
Healthcare administrations for correctional facilities are concerned that the high 
occurrence of HCV infection among incarcerated populations combined with the steep 
cost of HCV treatment will overwhelm already constricted healthcare budgets. Hence, the 
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cost of a treatment program for HCV is most likely the largest challenge facing the 
establishment of diagnosis and treatment programs.  
However, the development of efficient systemic approaches to testing and 
evaluation for treatment will drastically reduce the number of inmates eligible for 
treatment. As previously stated, only those with advanced infection and liver disease will 
receive treatment. Furthermore, inmates will be excluded from treatment if their period of 
incarceration is not long enough to cover the full course of treatment.  
Specifically, in Rhode Island correctional systems, only a very small fraction of 
HCV-infected inmates received treatment.  Between 1997 and 2000, 349 tested positive 
for HCV infection. Of this number, ninety were eligible for treatment.   In order to 
become eligible for treatment, inmates were required to meet a list of criteria.  Among the 
requirements, inmates had to have at least fifteen months left to serve.  This would ensure 
that enough time was available for treatment and follow-up.   In addition to this, patients 
had to be psychiatrically cleared on a case by case basis and those who had a history of 
substance abuse had to either enter a substance abuse treatment or had to have been sober 
for at least one year.  Of the inmates eligible for treatment, forty-one of them completed 
the full course of treatment while the remaining forty-nine were assumed to have 
completed half the course.  At the time, the cost of one course of antiviral treatment was 
about $9,500; thus, the estimated total cost was $622,250.  This represented about 5% of 
the total health care budget of the Rhode Island Department of Corrections.  Overall, this 
expense was not overburdening to Rhode Island's healthcare budget (Hammett, 2003).  
Also, an advantage of antiviral treatment for HCV is that unlike treatment for HIV which 
involves ongoing medical attention, it is only given for one course and then it is 
completed, thus   
Besides cost, other factors will challenge the feasibility of the integration of HCV 
prevention, diagnosis and management programs in correctional facilities.  Some 
constraints include a limited working staff as well as other healthcare priorities which 
may compete with HCV care.  Also, a devoted cooperation and communication between 
correctional health and public/private health-care practices needs to be established. 
Moreover, incarcerated populations are relatively disliked and ostracized by the general 
public.  The combined lack of political power and influence makes it easy for 
government officials to overlook their needs (Hammett, Harmon & Rhodes, 2002). 
 
The Current Evaluation and Management Practices for the Treatment of 
Hepatitis C in Massachusetts Correctional Facilities  
The process by which Massachusetts inmates are screened and evaluated for HCV 
treatment involves a methodical and thorough series of steps. To start with, instructive 
resources such as peer education and counseling on preventative measures are available 
to all inmates, regardless of their HCV status. Information offered covers the symptoms 
of HCV, ways the disease can be contracted, treatment options, and the side effects 
associated with treatment. Additionally, infected inmates are informed of behaviors 
which could exacerbate their condition, such as alcoholic intake which will augment liver 
damage. 
 10
Screening for Treatment Eligibility 
During their entry medical evaluation, an individual’s likelihood of HCV 
infection is assessed through the inmates’ history of several risk factors. If the individual 
has a history of intravenous drug use, has received a blood transfusion before July of 
1992, has had multiple sexual partners and/or has had a sexual partner with HCV, then 
he/she is deemed at high risk for having contracted the disease. Only one affirmation to 
these experiences is needed to qualify for an HCV antibody test. If the individual tests 
positive for HCV antibodies, then liver function tests are checked periodically. During 
this time, hepatitis A and hepatitis B statuses are checked and the individual is 
immunized for hepatitis A and hepatitis B, if possible (Brewer, Marshall, Demaria, 
2007).  
 After one year has passed since the HCV antibodies were detected, the HCV RNA 
viral load is measured. If the individual tests positive for HCV RNA, then he/she 
undergoes a series of both medical and laboratory evaluations to determine his/her 
eligibility for a liver biopsy. The medical evaluation ensures that the inmate has no 
history of renal transplantation, decompensated cirrhosis, severe depression, major 
medical illnesses such as diabetes or chronic obstructive pulmonary disease (COPD), 
intravenous drug use or alcohol use within the past twelve months, or disciplinary reports 
within the past year involving substance abuse. In addition, individuals should show no 
evidence of any autoimmune disease and, if female, should not be pregnant. Failure to 
meet these criteria will most likely exclude an HCV infected individual from continuing 
with the treatment evaluation process.  
 The laboratory segment of the evaluation process consists of white blood count, 
serum creatine, platelet, bilirubin, albumin and prothrombin level measurements. In most 
cases, abnormal levels for these labs will prevent an individual from proceeding onto a 
liver biopsy. However, abnormal lab values are not an absolute contraindication for 
continuing with the treatment qualification process. An antibody test for HIV is also 
implemented to determine if the patient should be referred to the HIV/HCV co-infection 
clinic. 
 Upon satisfying the criteria for both the medical and laboratory assessments, the 
HCV infected person will undergo a liver biopsy. Liver biopsies provide the physician 
with evidence on whether or not moderate inflammation and/or fibrosis of the liver are 
occurring. Treatment is not recommended if the liver biopsy is fairly normal, but it is 
recommended when the health status of the liver is compromised. 
Pre-treatment Protocol 
Once HCV treatment is recommended, the Hepatitis C worksheet (Appendix A) must 
be filled out and sent to the Hepatitis C Program Manager in the UMass Correctional 
Health Program of UMass Medical School. The Hepatitis C Program Manager oversees 
the treatment waiting list for all HCV infected inmates in the seventeen Massachusetts 
correctional facilities.  As of February 2007, there were sixty-eight inmates on therapy 
and twenty on the waitlist. The maximum number of inmates allowed on HCV therapy at 
one time is ninety-five. It is part of the manager’s responsibility to update records as well 
as keep track of who is currently on therapy and which individuals are next on the 
waitlist. Inmates who have been approved to receive treatment but are on the waitlist are 
divided into 4 categories: 
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1. Treatment naïve 
a. Genotype 1, 2, 3 and 4 
2. Dual Diagnosis (HCV/ HIV) 
a. Fulminant (go to top of list) 
b. Non-Fulminant 
3. Relapsers, Treatment Failures and Non-Responders after Interferon/Ribavirin 
Combination Therapy 
4. Date of biopsy and length of time since biopsy will be considered 
 
The selection of patients to be treated occurs in increments of ten. Five individuals 
from category one, two to three from category two, and two to three patients from 
category three are chosen.  Patients classified under the “Fulminant Dual Diagnosis” 
category are given top priority for treatment.  They are the most critically sick, and as a 
result, are moved to the top of the list regardless of the date they were diagnosed.  
Additional factors which place a higher urgency to treat include the severity of the liver 
biopsy as well as the length of time a patient has been waiting on the treatment waitlist. 
Each patient in a group of ten will receive treatment before an additional group of ten 
inmates is to be selected (Brewer, Marshall, Demaria, 2007).  
 Prior to initiating HCV therapy, several parameters must be addressed. First of all, 
it must be verified that the patient will be incarcerated for greater than one year after 
treatment begins. A short sentence prevents patients from receiving a complete course of 
treatment as well as follow-up testing to monitor their HCV status and evaluate treatment 
effectiveness. Secondly, a full history and physical examination must be conducted and 
recorded on the Hepatitis C worksheet (Appendix A).  Patients with certain other health 
conditions must undergo additional testing before they can be cleared for therapy.  For 
example, patients with a history of coronary artery disease are required to have an EKG 
and possibly a stress test, while patients with diabetes should be tested for fasting glucose 
and hemoglobin levels.  
 The next step requires the patient to read, understand and sign the “Inmate 
Agreement” form (Appendix B). This sheet represents the patient’s consent to begin 
treatment. By signing this form, the patient acknowledges his/her understanding of the 
disease process, its effects on their health, treatment options, side effects of treatment and 
the varying levels of success experienced by different HCV infected patients on 
treatment. The patients must acknowledge all of the health risks associated with therapy 
and must inform the medical staff of any symptoms. They must also pledge to avoid 
illegal drug and alcohol use, and tattoos. Infringing upon these rules will result in 
termination of treatment. 
 Another step before initiating therapy is the measurement of several baseline lab 
values, the most important being the HCV RNA viral load just prior to treatment. Others 
include ALT, white blood cell, hemoglobin, hematocrit, platelets, cholesterol, 
triglycerides, glucose, albumin and thyroid stimulating hormone (TSH) levels. Woman 
must take a pregnancy test to verify they are not pregnant while on treatment. Once 
treatment is initiated, patients are closely monitored by the medical staff to ensure they 
are comfortable on therapy and remain symptom free. As previously mentioned, common 
side effects of pegylated interferon and ribavirin are flu-like symptoms, nausea, 
abdominal discomfort, loss of appetite, edema, rash, reactions at injection site, muscle 
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aches, loss of hair and symptoms associated with depression (Brewer, Marshall, Demaria, 
2007). 
The Process of HCV Therapy 
The most commonly used medications for the treatment of HCV are pegylated 
interferon and ribavirin. This combination therapy is recommended for all patients except 
for those with special circumstances, such as patients who are co-infected with HIV and 
HCV. After twelve weeks of HCV therapy, the HCV RNA viral load is tested. Only if 
there is at least a two log reduction of the HCV RNA viral load will the treatment be 
continued. If there is less than a two log reduction, the patient is considered unresponsive 
to treatment.  In this case, the medication is discontinued and the patient is then closely 
monitored in chronic care.  A full course of HCV therapy for genotypes 2 and 3 is 
twenty-four weeks while for other genotypes it is forty-eight weeks. The HCV-RNA viral 
load is again measured at the completion of treatment as well as six months after therapy 
ends to assess for a sustained anti-viral response.  
 In addition to HCV RNA viral loads, complete blood counts are drawn throughout 
the course of treatment to examine the effects of the medications on hemoglobin, white 
blood count, neutrophils, platelets, hematocrit, ALT, TSH, and viral load levels. If 
hemoglobin levels drop, the dosage of ribavirin is decreased. If the white blood cell 
count, absolute neutrophils and platelets drop, then pegylated interferon is decreased.  
Besides blood tests, females must also take a pregnancy test every month during therapy 
(Brewer, Marshall, Demaria, 2007).  
The overall evaluation process for the management and treatment of hepatitis C 
infected inmates in Massachusetts facilities are summarized in the flow charts found on 
the following pages. 
Inmates Co-infected with HIV and HCV 
In order to be referred to the HIV/HCV co-infection clinic, the patient must have 
tested positive for HIV antibodies or detectable HIV RNA as well as have a positive 
HCV antibody test or evidence of HCV RNA. Similar to mono-infected inmates, liver 
function tests along with baseline labs should be drawn including complete blood counts, 
CD4 counts and percentages, albumin, prothrombin, and HIV RNA levels. Evaluation by 
the gastroenterologist and the infectious disease specialist will determine whether or not a 
liver biopsy will be conducted. An additional right upper quadrant ultrasound is to be 
done before the biopsy. If chronic HCV infection along with HIV viremia is present, 
Pegasys plus/minus ribavirin will be recommended as therapy if no other 
contraindications exist. A closer follow-up is necessary with co-infected patients in order 
to monitor for the expected side effects as well as the potential for other severe symptoms 
to occur. For some co-infected patients on treatment, antiretroviral therapy has had to be 
terminated due to hepatotoxicity. Other patients must have frequent endoscopies if their 
cirrhosis worsens in order to verify whether or not they have esophageal varices (Brewer, 
Marshall, Demaria, 2007).  
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If inmate is at high risk of 
HCV infection, then they 
must take an HCV antibody 
test. 
If negative HCV 
antibody test; then 
counseled on HCV 
prevention 
If tested for positive HCV antibody; 
- observed for 1 year 
- periodic liver function tests 
- immunized to Hep A & Hep B 
Peer education and counseling for all inmates. 
Entry examination; assessment of risk behaviors 
Non-Detectable 
HCV RNA; 
counseled on 
prevention 
After 1 year, 
check HIV RNA 
viral load 
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If presence of HCV RNA is detected, then patient must 
undergo a medical and laboratory evaluation. Only if 
patient meets the inclusion criteria for both the medical 
and laboratory evaluations can they be referred for a 
liver biopsy. 
Medical consultation to 
perform liver biopsy. 
Physician evaluates liver 
biopsy for signs of 
inflammation/ fibrosis 
HCV treatment 
not 
recommended 
HCV treatment recommended 
Prior to treatment 
- Review/sign Inmate Agreement form 
- Full History & Physical Exam; information transferred to     
Hep C Worksheet and sent to Hepatitis C Program Manager 
Placed on waitlist 
- make sure incarceration period is at least 1 year at start of treatment 
- must be sober for at least 1 year before treatment begins 
 15
Begin HCV Therapy 
-Must have baseline labs measured prior to treatment 
initiation (HCV RNA is most important) 
-Certain labs are measured throughout course of treatment 
according to treatment lab protocol 
HCV RNA viral 
load measured at 12 
weeks into treatment 
Less than a 2 log 
reduction of HCV 
viral load; Discontinue 
therapy
2 log or greater 
reduction of HCV 
RNA viral load; 
Continue treatment 
Continue 
follow-up of 
patient in 
chronic care 
HCV RNA viral load measured at completion of 
full course of therapy (24 or 48 weeks)  
Measure HCV RNA viral load 6 months post therapy to check for 
sustained response 
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The HCV Database 
The prospect of establishing hepatitis C management programs in correctional 
facilities does seem ideal considering that such a large percentage of people infected with 
HCV are in a confined setting.  It has become apparent to several states that the period of 
incarceration provides a window of opportunity to screen, evaluate and treat those at risk 
for hepatitis C.  Among the states which have implemented a hepatitis C treatment 
program in correctional facilities is Massachusetts.  In 2004, a database was created to 
monitor and assess the treatment of hepatitis C infected individuals in Massachusetts 
correctional facilities.  As of March 2005, 262 inmates treated were entered into this 
database.  An analysis conducted for this data set revealed that the majority of inmates 
treated were Caucasian, male and infected with HCV genotype 1.  The database also 
provided information regarding treatment response and success rates; almost half of the 
inmates treated had achieved a successful response, reaching an undetectable HCV viral 
load (Kelly, 2005). 
The purpose of this project was to update the database with additional inmates 
who were treated up until February 2007.  After the medical and treatment information 
from the forms of these inmates were transferred into the database, a demographic 
analysis was performed such that the characteristics (gender, race, age, facility) of 
inmates treated could be summarized. A demographic synopsis provided a review of who 
is treated with the benefit of minimizing any intentional or unintentional bias.  
Predispositions of the facilities to treat certain populations over others can be exposed 
through this analysis, providing the management incentive to review protocols.  
Response to treatment was similarly assessed based on lab results entered in the 
database.  HCV RNA viral loads and ALT levels proved to be important indicators of 
treatment success.  Consequently, HCV RNA levels were used to examine any 
correlations between the success of treatment and viral genotype as well as HIV co-
infection.  Results have shown that inmates with genotype 1 have the least successful 
responses when compared with genotypes 2, 3 and 4.  In addition, co-infection with HIV 
was found to drastically reduce the chance of successful treatment outcomes.  
Other major components looked at in the database were reasons for treatment 
interruptions and causes of premature termination of treatment.   Among others, these 
included severe and intolerable side effects, poor anti-virological response to the 
medications, and early release from prison.  Although an inadequate amount of data was 
available to perform a quantitative analysis, a qualitative evaluation of the reasons for 
unsuccessful and incomplete courses of treatment may serve as a reference for improving 
upon the efficiency of the screening and treatment protocols. Several recommendations 
for improvements in the database included the collection of missing data and the 
development of a stricter follow-up system.  Variables such as inmates' history of 
substance abuse and the presence of mental and physical health conditions were missing 
data for nearly half the inmates.  Follow-up HCV RNA measurements were similarly 
missing for an even larger percentage of inmates. This information is vital in determining 
the success rate of treatment.  
The value of the hepatitis C treatment database for HCV infected inmates in 
Massachusetts correctional facilities is in its contributions to the limited knowledge of 
this disease and its management.  Despite the large proportion of HCV infected people 
who pass through a correctional facility, there is still a shortage of factual and statistical 
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information on HCV infection among inmates.  Not having a database for tracking HCV 
incidence and treatment contributes to the absence of a standardized system of health care 
and treatment programs in correctional settings.  The collection of more data in 
correctional facilities would allow for the better understanding of hepatitis C prevalence 
as well as the effectiveness of its treatment.  Ideally, more facilities will follow in the 
footsteps of the Massachusetts treatment program and employ an efficient system of data 
collection and organization. 
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Materials and Methods 
 This project was conducted over a six month period, from November 2006 to 
April 2007.  During this time, research was approved, data was collected, and the SPSS 
database was revised and updated.  An analysis of the data was used to assess the effects 
of changes made to the original data collection process as well as examine the current 
state of hepatitis C treatment in Massachusetts state correctional facilities.   
 Research Preparation 
 Preparation for data collection and handling began as early as November 2006.  
Prior to the start of any clinical research project, an intensive review must be conducted 
by the Institutional Review Board (IRB).  The IRB is a review committee typically 
composed of five members of various sexes, backgrounds, and professions.  It was 
originally created in the 1970’s to help protect the rights and welfare of human research 
subjects by ensuring that clinical studies are well designed, ethical, legal, and safe.  IRBs 
have the authority to modify, approve, or disapprove any research study involving human 
subjects after an extensive review of the proposed course of action.  Most research 
institutions, professional organizations, and scholarly journals have established IRBs 
(Epley, Erickson, and Selwitz, 2006; National Cancer Institute [NCI], n.d.). 
 For this particular project, data collection could not begin until an IRB training 
course had been completed by each individual researcher.  The Collaborative IRB 
Training Initiative (CITI) is an online course in the protection of human research subjects 
that is required by the University of Massachusetts, Worcester.  It is comprised of various 
training modules regarding the history of the IRB, the function of the IRB, and the 
conduction of research involving different human populations including vulnerable 
subjects such as prisoners.  Completion of the course required a review of each module as 
well as a corresponding quiz.  Individual certificates of completion were received at the 
conclusion of the course and sent for approval by the IRB at the University of 
Massachusetts, Worcester as well as the Massachusetts Department of Correctional 
Facilities.  Complete IRB approval was achieved by December 2006.    
Data Collection 
 Data was collected for this project over a two month period, from January 1, 2007 
to March 1, 2007.  Demographic, health, and treatment-related information was gathered 
on a total of 177 inmates including 109 inmates now off treatment and sixty-eight 
inmates currently on treatment.  Data for each inmate was extracted directly from 
individual hepatitis C worksheets (Appendix A) completed and stored in the medical 
records file of each individual. 
 The current hepatitis C worksheet is a one-page record of inmate history and 
treatment.  It contains basic information such as name, age, race, weight, and height; a 
brief medical history including current health or mental health conditions, a history of 
alcohol or drug abuse, and a history of co-infection; as well as treatment-related data such 
as treatment start and end date, lab figures, changes in treatment, and any necessary 
notes.  Originally, the hepatitis C worksheet was a two-page treatment record updated 
regularly by nurses and doctors (Appendix C).  However, when data collection began in 
2004, information from these original worksheets was extracted and transferred to a more 
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organized data collection worksheet (Appendix D). Although this worksheet included all 
the information necessary to monitor the progress of the inmates and the types of inmates 
being treated, the extensive length of the paperwork resulted in an increasing amount of 
missing data.  On September 27, 2004, a new one-page hepatitis C worksheet was created 
and later revised to the current worksheet in 2005 (Appendix A).  This treatment record is 
typically filled out prior to the start of treatment by HIV/Hepatitis C case managers at 
each health service unit.  Following the start of treatment, sheets are transferred and 
information is continually updated by the Hepatitis C Program Manager for UMass 
Medical School and the UMass Correctional Health Program. 
 In order to maintain the confidentiality of inmates during the data collection 
process, names were blacked out and inmates were coded with an arbitrary five digit 
number beginning with 55 or 88.  A 55 number indicated inmates with data from the old 
hepatitis C worksheets, while an 88 number indicated inmates with data from the new 
hepatitis C worksheets.  All data input over the course of this project was extracted from 
the new worksheets.  This included updated information for inmates that had already 
completed or discontinued treatment in the past three years, old data from 2004 and 2005, 
and new data for inmates that had recently started treatment.    
 Differences were noted in the amount of information each worksheet contained.  
Worksheets completed within the past year were nearly, if not entirely, complete.  Older, 
worksheets, however, were frequently missing large amounts of important information 
such as height, weight, incarceration date, current health conditions, history of alcohol or 
drug abuse, and reasons for any discontinuation of or interruptions in treatment.  It was 
unclear as to whether or not this data was actually missing, unknown, or not applicable.  
In either case, all data considered missing was compiled into various “missing data logs” 
and sent to the program manager who had direct contact with inmates and case managers 
and could potentially retrieve necessary data.   
Data Entry 
 All information collected during the course of this project was input into an SPSS 
database.  SPSS for Windows is an analytical software program devised by SPSS Inc. for 
data collection, data access, data management and preparation, statistical data analysis, 
and reporting (SPSS Inc., 2007).  Actual data entry was conducted in a large SPSS 
spreadsheet.  Different rows indicated different inmates whereas different columns 
indicated different fields of data associated with the hepatitis C worksheet.  Assigned row 
numbers and specific column headers were used to differentiate inmates and identify data 
requirements, respectively.  Inmates were numerically ordered in the database according 
to their assigned five digit code beginning with 55 or 88.   All data was entered into the 
appropriate rows and columns based on specific variables previously coded into the SPSS 
system.  Number as well as word variables were used to define available and unknown 
data.  Missing information was indicated in the database by blank fields.   
Data Analysis 
 Between March 2007 and April 2007, a statistical analysis of the complete data 
set was conducted using the SPSS program.  The analysis was focused primarily on 
characterizing the types of inmates being treated, summarizing the overall progress of 
hepatitis C treatment, and identifying potential trends or correlations between inmate 
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characteristics and the success of treatment.  Only those fields of data which had limited 
amounts of missing information in the database were assessed.   
 To account for the changes that have taken place in hepatitis C treatment since 
1999, data was analyzed based on one of two different categories:  inmates who have 
received treatment since 1999 and inmates who have received treatment since August 
2002.  February 1999 marked the start of hepatitis C treatment for inmates in the 
database, whereas August 2002 marked the start of combination therapy as the standard 
form of treatment in Massachusetts state correctional facilities.  Creation of the two 
categories allowed for a more accurate assessment of the types of inmates being treated 
and the current progress of treatment.  
 For inmates who had received treatment since 1999, data analyses were conducted 
to summarize the trends in inmate characteristics and treatment center operations that 
were unaltered by the 2002 changes in hepatitis C treatment.  In particular, data was used 
to assess inmate demographics such as gender, age, and race, the frequency of genotypes 
among inmates, and the frequency of treatment at each treatment center.  Assessments of 
additional information such as health conditions, mental health conditions, and prior 
history of substance or alcohol abuse were not made due to the large percentage of 
missing data in these fields.   
 Although the 2002 changes in standard treatment did not affect the types of 
inmates who had received treatment since 1999, they could have affected the overall 
outcome and progress of treatment.  In order to accurately assess these effects, treatment 
related data was only analyzed for those inmates who had received treatment since 
August 2002.  Data was used specifically to assess variations in ALT and HCV RNA 
levels prior to the start of treatment, the frequency of undetectable viral loads attained by 
the end of treatment, the frequency of genotypes among inmates and their potential 
correlation with treatment outcome, the frequency of HIV co-infection among inmates 
and its potential correlation with treatment outcome, the frequency of treatment 
interruption, and the frequency of treatment discontinuation as well as the reasons given 
for stopping treatment.  Any additional assessments were deemed unnecessary or could 
not be made due to missing data constraints.  
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Results 
  To account for the division in statistical analyses, results have been classified 
under two different categories:  inmate characteristics and response to treatment.  Each 
category is based on a specific set of inmates whose data was used to assess a number of 
different fields. The results for each analyzed field have been individually summarized 
within their corresponding category and are based on statistical data tables originally 
output by SPSS.  Summaries are characterized by verbal highlights, graphs, and tables 
similar to those generated by SPSS.    
 All results have been organized by SPSS in terms of valid and missing data.  
Valid is an expression used to define all known and legitimate data that has been input 
into the database.  Missing, on the other hand, is an expression used to define all data that 
is either missing from the database, has been input into the database as unknown, or has 
been incorrectly input into the database as an undefined variable.  Undefined variables 
and unknown data are specifically referred to as unknown, whereas data missing from the 
system is referred to by the term system.    
 Results from the actual SPSS analysis of valid and missing data are presented in 
three different forms:  frequency, percent, and valid percent.  “Frequency” refers to the 
actual number of inmates that fall within a given category.  This result represents the total 
number of inmates analyzed within a given field, and thus includes all valid and missing 
data.  “Percent” is the calculated percentage of inmates within a given category based on 
the total number of inmates analyzed.  This, again, represents the total number of inmates 
analyzed and includes both valid and missing data.  “Valid Percent” is the only result that 
does not include missing data.  It is the calculated percentage of inmates within a given 
category based solely on the total number of inmates with valid data.   
 Due to the extent of missing data in the database, the total number of inmates with 
valid data was not equivalent to the number of inmates analyzed within each field.  
However, these figures were the most accurate representation of the data within the 
database.  Consequently, valid frequencies and valid percents were used to summarize the 
results of each field.    
Inmate Characteristics 
 The following results are based on all inmates who have received treatment since 
1999.  This year marked the start of hepatitis C therapy for inmates included in the 
database.  As of March 1, 2007, data on a total of 510 treated inmates has been collected 
and input into the HCV database.  This data was used to assess the overall characteristics 
of inmates receiving treatment including the facility at which they first began treatment 
as well as their gender, age, race, and HCV genotype.      
Facility at Start of Treatment 
 Out of 510 inmates treated, 479 (93.9%) inmates had a documented name for the 
correctional facility at which their treatment was initiated.  A total of 17 correctional 
facilities were identified as having provided hepatitis C treatment since 1999.  The 
number of inmates treated varied among the facilities, ranging from as low as 2 inmates 
to as high as 78 inmates.  The majority were treated at Massachusetts Correctional 
Institution - Norfolk (78), Souza-Baranowski Correctional Center (71), and 
Massachusetts Correctional Institution – Shirley (66).  A limited number of inmates 
 22
received treatment at the Massachusetts Alcohol and Substance Abuse Center (2), Old 
Colony Correctional Center Min (3), Bridgewater State Hospital (4), and Massachusetts 
Correctional Institution - Plymouth (4).  Results for all 17 correctional facilities have 
been summarized in Table 1.  A bar graph of the number of inmates treated at each 
facility at the start of treatment is shown in Figure 1.    
 
Table 1:  Frequency and Percentage of Inmates among Massachusetts State Correctional Facilities at    
  the Start of Treatment 
 
Facility Number of Inmates Percent Valid Percent 
Baystate 27 5.3 5.6
Bridgewater 4 0.8 0.8
Concord 16 3.1 3.3
Concord Farm 14 2.7 2.9
Framingham 15 2.9 3.1
Gardner 49 9.6 10.2
MASAC 2 0.4 0.4
Norfolk 78 15.3 16.3
OCCC 54 10.6 11.3
OCCC Min 3 0.6 0.6
Pondville 5 1 1
Plymouth 4 0.8 0.8
Shirley Medium 66 12.9 13.8
South Middlesex 6 1.2 1.3
Souza Baranowski 71 13.9 14.8
Treatment Center 13 2.5 2.7
Walpole 52 10.2 10.9
Valid 
Total 479 93.9 100
Unknown 6 1.2   
System 25 4.9   
Missing 
Total 31 6.1   
Total   510 100   
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      Figure 1:  Distribution of Inmates among Massachusetts State Correctional Facilities at the Start  
             of Treatment 
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Gender 
 Out of 510 inmates treated, 484 (94.9%) inmates had a documented gender.  467 
(96.5%) of those inmates were male, whereas only 17 (3.5%) of those inmates were 
female.  All 17 female inmates received hepatitis C treatment at either the Massachusetts 
Alcohol and Substance Abuse Center (MASAC) or Massachusetts Correctional 
Institution – Framingham (MCI – Framingham).  Statistical results for the frequency of 
male and female inmates treated have been summarized in Table 2 and graphed in Figure 
2. 
Table 2:  Frequency and Percentage of Male and Female Inmates Treated 
Gender Number of Inmates Percent Valid Percent 
Male 467 91.6 96.5
Female 17 3.3 3.5
Valid 
Total 484 94.9 100
Unknown 1 0.2   
System 25 4.9   
Missing 
Total 26 5.1   
Total   510 100   
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Figure 2:  Distribution of Male and Female Inmates Treated 
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Race 
The race/ethnicity of those treated for HCV in Massachusetts Correctional 
facilities was recorded for 356 (69.8%) of the inmates in the database. According to the 
known data, Caucasians were the most frequently treated race with 224 (62.9%) inmates. 
Hispanic/Latino and African Americans were nearly tied for the second highest 
race/ethnicity treated for HCV in MA facilities. There were 66 (18.5%) Hispanic/Latino 
inmates treated while there were 63 (17.7%) African Americans treated. One (0.3%) 
Native American and two (0.6%) inmates classified under “other ethnicity” were treated. 
Table 3 contains all of the frequencies and percentages of the inmates’ ethnicities and 
Figure 3 displays the valid percentages of the inmates’ race/ethnicities. 
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Table 3:  Frequency and Percentage of Race/Ethnicity among Inmates Treated 
Race/Ethnicity Number of Inmates Percent Valid Percent 
Caucasian 224 43.9 62.9
Black/African 
American 
63 12.4 17.7
Hispanic/ Latino 66 12.9 18.5
Native American 1 0.2 0.3
Other 2 0.4 0.6
Valid 
Total 356 69.8 100
Unknown 87 17.1  
System 67 13.1  
Missing 
Total 154 30.2  
Total   510 100  
 
Figure 3:  Race/Ethnicity of Inmates Treated 
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Age 
 A majority of the information regarding the ages of the inmates at the start of 
HCV therapy was entered into the database; out of the 510 inmates, 475 (93.1%) had a 
recorded age. The ages of those inmates who started treatment ranged from as young as 
22 to as high as 71 years old. The majority of those individuals on HCV therapy began 
treatment when their age fell within the range of middle thirties to late forties. The two 
ages which had the highest number of inmates treated (28 patients), were 42 and 45 years 
old. The average age of inmates beginning treatment was 42.9 while the median was 43 
years old. See Table 4 for the complete age data set. Figure 4 shows the number of 
inmates who started therapy at each specific age. 
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Table 4:  Age of Inmates at the Start of Treatment 
Age  Number of Inmates Percent Valid Percent 
22 1 0.2 0.2
24 2 0.4 0.4
26 5 1 1.1
27 7 1.4 1.5
28 5 1 1.1
29 9 1.8 1.9
30 8 1.6 1.7
31 10 2 2.1
32 14 2.7 2.9
33 5 1 1.1
34 8 1.6 1.7
35 8 1.6 1.7
36 18 3.5 3.8
37 12 2.4 2.5
38 20 3.9 4.2
39 26 5.1 5.5
40 26 5.1 5.5
41 23 4.5 4.8
42 28 5.5 5.9
43 20 3.9 4.2
44 20 3.9 4.2
45 28 5.5 5.9
46 18 3.5 3.8
47 20 3.9 4.2
48 21 4.1 4.4
49 20 3.9 4.2
50 11 2.2 2.3
51 10 2 2.1
52 14 2.7 2.9
53 9 1.8 1.9
54 5 1 1.1
55 10 2 2.1
56 9 1.8 1.9
57 5 1 1.1
58 3 0.6 0.6
Valid 
59 7 1.4 1.5
  60 6 1.2 1.3
  64 1 0.2 0.2
  68 1 0.2 0.2
  69 1 0.2 0.2
  71 1 0.2 0.2
  Total 475 93.1 100
Unknown 8 1.6   
System 27 5.3   
Missing 
Total 35 6.9   
Total   510 100   
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Figure 4:  Age Distribution at Start of Treatment 
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HCV Genotype 
 A summary of viral genotype groups was conducted from the 440 (86.3%) 
inmates who had a recorded HCV genotype in the database. With a frequency of 291 
(66.1%), the majority of inmates were infected with HCV genotype 1. 78 (17.7%) 
inmates were infected with genotype 3 while 51 (11.6%) inmates were infected with 
genotype 2. Only 20 (4.5%) inmates had genotype 4. Table 5 lists the frequencies and 
percentages of the HCV genotypes. Figure 5 displays the distribution of HCV genotype 
groups among infected inmates who began treatment.  
 
Table 5:  Frequency and Percentage of HCV Genotypes among Inmates Treated 
HCV Genotype Number of Inmates Percent Valid Percent 
Genotype 1 291 57.1 66.1
Genotype 2 51 10 11.6
Genotype 3 78 15.3 17.7
Genotype 4 20 3.9 4.5
Valid 
Total 440 86.3 100
Unknown 39 7.7  
System 31 6.1  
Missing 
Total 70 13.7  
Total   510 100  
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Figure 5:  Distribution of HCV Genotypes among Inmates Treated 
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Response to Treatment 
 The following results are based on all inmates who have received treatment since 
August 2002.  This date marked the start of combination therapy (interferon + ribavirin) 
as the standard form of treatment in Massachusetts state correctional facilities.  As of 
March 1, 2007, a total of 370 inmates have been documented in the database as having 
received treatment since August 2002.  Data from these inmates was used to assess the 
overall response of inmates to treatment including variations in ALT and HCV RNA 
levels prior to the start of treatment, the frequency of undetectable viral loads attained by 
the end of treatment, the frequency of genotypes among patients and their potential 
correlation with treatment outcome, the frequency of HIV co-infection among patients 
and its potential correlation with treatment outcome, the frequency of treatment 
interruption, and the frequency of treatment discontinuation as well as the reasons given 
for stopping treatment. 
Baseline ALT Levels 
 Out of 370 inmates treated, 302 (81.6%) inmates had a documented baseline value 
for the level of alanine aminotransferase (ALT) in the blood.  These values were 
measured in terms of International Units per Liter (IU/L).  Typically, in a normal and 
healthy individual, ALT levels in the blood tend to range between 0 and 40 IU/L 
(Franciscus and Teeter, 2006). According to the labs of inmates treated, baseline ALT 
levels ranged from 12 IU/L to 627 IU/L.  The average ALT level was calculated around 
90.26 IU/L, whereas the median ALT level was approximately 68 IU/L.  The majority of 
inmates (60.5%) had baseline ALT levels between 30 IU/L and 79 IU/L.  Due to the large 
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percentage of missing data, ALT levels at 12 weeks and 24 weeks into treatment could 
not be assessed.  Refer to Table 6 for all relative data figures and percentages and Figure 
6 for a bar graph of the number of inmates and their associated baseline ALT levels. 
 
Table 6:  Baseline ALT Levels among Inmates Treated 
Baseline ALT Level Number of Inmates Percent Valid Percent 
< 20 4 1.1 1.3
20 – 29 13 3.5 4.3
30 - 39 22 5.9 7.3
40 - 49 46 12.4 15.2
50 - 59 28 7.6 9.3
60 - 69 44 11.9 14.6
70 - 79 30 8.1 9.9
80 - 89 17 4.6 5.6
90 - 99 13 3.5 4.3
100 - 109 14 3.8 4.6
110 - 119 8 2.2 2.6
120 - 129 7 1.9 2.3
130 - 139 6 1.6 2
140 - 149 7 1.9 2.3
150 - 159 2 0.5 0.7
160 - 169 7 1.9 2.3
170 - 179 2 0.5 0.7
180 - 189 5 1.4 1.7
190 - 199 6 1.6 2
200 - 209 2 0.5 0.7
210 - 219 6 1.6 2
220 - 229 1 0.3 0.3
230 - 239 1 0.3 0.3
240 - 249 2 0.5 0.7
> 249 9 2.4 3
Valid 
Total 302 81.6 100
Unknown 0 0   
System 68 18.4   
Missing 
Total 68 18.4   
Total   370 100   
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Figure 6:  Distribution of ALT levels at the Start of Treatment 
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HCV Viral Load 
 Out of 370 inmates treated, 332 (89.7%) inmates had a documented baseline value 
for the level of HCV RNA in the blood.  These values were measured in terms of 
International Units per milliliter (IU/mL).  Baseline HCV RNA levels ranged from as low 
as 353 IU/mL to as high as 98,400,000 IU/mL.  The average HCV RNA level was 
calculated around 2,363,344.53 IU/mL, whereas the median HCV RNA level was only 
1,131,740 IU/mL.   
 Due to the large percentage of missing data, HCV RNA levels at 12 weeks, 24 
weeks, and 48 weeks into treatment could not be assessed.  However, results did show 
that inmates achieved an undetectable viral load (<615 IU/mL) as early as 12 weeks into 
treatment.  Of the 232 inmates who had HCV RNA levels recorded beyond the baseline 
value, 178 (76.7%) of them achieved an undetectable viral load by the end of treatment.  
Not enough data was available to summarize the number of inmates who were able to 
attain a sustained virologic response.    
 Results regarding the frequency of undetectable HCV viral loads among inmates 
have been outlined in Table 7.  
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Table 7:  Undetectable Viral Loads among Inmates Treated 
Did Subject Have Undetectable 
HCV Viral Load? 
Number of 
Inmates Percent Valid Percent 
No 54 14.6 23.3
Yes 178 48.1 76.7
Valid 
Total 232 62.7 100
Unknown 43 11.6   
System 95 25.7   
Missing 
Total 138 37.3   
Total   370 100   
 
Correlation between HCV Genotype and Success of Treatment 
 Out of 370 inmates treated, 217 (58.6%) inmates had a documented HCV 
genotype as well as HCV RNA levels recorded beyond the baseline value.  Of the 149 
inmates infected with HCV genotype 1, 106 (71.1%) of them achieved an undetectable 
viral load (<615 IU/mL) by the end of treatment.  Of the 68 inmates infected with HCV 
genotypes 2, 3, or 4, 62 (91.2%) of them were able to achieve a similar success in 
treatment with an undetectable viral load (<615 IU/mL).  Statistical results regarding the 
correlation between HCV genotype and an inmate’s ability to achieve an undetectable 
viral load (< 615 IU/mL) have been summarized in Table 8. 
 
Table 8:  The Effect of HCV Genotype on HCV Viral Loads  
Genotype 
Did Subject Have Undetectable 
HCV Viral Load? 
Genotype 1 Genotype Other  (2, 3, 4) 
Number of Inmates 43 6 
No 
Valid Percentage  within 
Genotype 28.90% 8.80% 
Number of Inmates 106 62 
Yes 
Valid Percentage  within 
Genotype 71.10% 91.20% 
Number of Inmates 149 68 
Total 
Valid Percentage  within 
Genotype 
100% 100% 
 
HIV Co-infection 
 255 (68.9%) of the 370 inmates on HCV combination therapy had a documented 
HIV status.  200 (78.4%) were only mono-infected with HCV while 55 (21.6%) inmates 
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were co-infected with HIV. Table 9 lists the data involving the HIV co-infection status of 
inmates on HCV therapy. Figure 7 shows the frequency of patients who were either 
mono-infected with HCV or co-infected with HCV and HIV. 
 
Table 9:  Frequency and Percentage of Inmates Co-infected with HIV 
Did Subject Have HIV Co-
infection? 
Number of 
Inmates Percent Valid Percent 
No 200 54.1 78.4
Yes 55 14.9 21.6
Valid 
Total 255 68.9 100
Unknown 81 21.9  
System 34 9.2  
Missing 
Total 115 31.1  
Total   370 100  
 
 
Figure 7:  Distribution of Inmates with HIV/HCV Co-infection 
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Correlation between HIV Co-infection and Success of Treatment 
 Out of the 370 inmates on combination therapy, only 165 (44.6%) inmates had a 
known HIV status and a recorded HCV viral load during or at the end of treatment. 
Despite the substantial amount of missing information, the recorded data between HIV 
status and treatment success was compared in an attempt to define any relationship 
between the two. Out of the 143 inmates who were only mono-infected with HCV, 116 
(81.1%) had achieved an undetectable HCV viral load. Out of the 22 inmates who were 
co-infected with HIV, 12 (54.5%) had achieved an undetectable HCV viral load. Table 10 
displays the cross-tabulation of data on whether or not the inmate was infected with HIV 
and whether or not he/she had reached undetectable HCV RNA levels. 
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Table 10:  The Effect of HIV Co-infection on HCV Viral Loads 
HIV Co-infection Did Subject Have Undetectable 
HCV Viral Load? No Yes 
Number of Inmates 27 10 No 
Valid Percentage  within HIV 
Co-infection 18.90% 45.50% 
Number of Inmates 116 12 Yes 
Valid Percentage  within HIV 
Co-infection 81.10% 54.50% 
Number of Inmates 143 22 Total 
Valid Percentage  within HIV 
Co-infection 
100% 100% 
 
Treatment Interruptions 
 223 (60.3%) inmates had documented information on whether or not they had 
experienced any treatment interruptions. From this known data, 40 (17.9%) inmates did 
have treatment interruptions while 183 (82.1%) inmates did not. These values and 
percentages are organized in Table 11.   
 
Table 11:  Number of Inmates Who Experienced Treatment Interruptions 
Did Subject have any Treatment 
Interruptions? 
Number of 
Inmates Percent Valid Percent 
No 183 49.5 82.1
Yes 40 10.8 17.9
Valid 
Total 223 60.3 100
Unknown 1 0.3  
System 146 39.5  
Missing 
Total 147 39.7  
Total   370 100  
 
Early Discontinuation of Treatment 
 From the total number of inmates on HCV combination therapy, 243 (65.7%) had 
recorded data on whether or not they had to stop treatment early. 137 (56.4%) inmates 
had prematurely terminated treatment while 106 (43.6%) inmates did not stop treatment 
early.  Table 12 lists data regarding the amount of inmates who have discontinued 
treatment before they had completed a full course of therapy. 
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Table 12:  Early Discontinuation of Treatment among Inmates 
Was Treatment Stopped Early? Number of Inmates Percent Valid Percent 
No 106 28.6 43.6
Yes 137 37 56.4
Valid 
Total 243 65.7 100
Unknown 6 1.6  
System 121 32.7  
Missing 
Total 127 34.3  
Total   370 100  
 
 
Reasons for stopping treatment early was input in the database and can be 
classified into three main categories: poor virologic response to treatment, severe side 
effects and poor compliance with treatment. According to the protocol followed by MA 
correctional facilities, if the patient did not reach a 2 log reduction in HCV RNA viral 
load by the twelfth week into treatment, then that person was discontinued from therapy 
because he/she was not responding to the medications. Several inmates stopped treatment 
early for this reason. 
As cautioned to the inmates before initiating therapy, HCV treatment may elicit 
several side effects. These side effects vary in degree and may be difficult to tolerate. 
Among the most common physical symptoms that were listed as reasons why treatment 
was stopped early are cotton wool spots, chest pain, rash, visual problems, back pain, and 
gastrointestinal problems including nausea, vomiting, and diarrhea. The mental health 
status of some inmates was also affected by the medications; other reasons for 
discontinuing treatment were anxiety, mood swings, agitation, and neurological 
symptoms including seizures and shakes. Other side effects which resulted in ending 
treatment early were anemia, and a decrease in hemoglobin, neutrophils and/or white 
blood cells. Experiencing severe side effects was the predominant category of reasons 
why treatment was terminated early. 
Before beginning treatment, inmates were advised to avoid any high-risk 
behaviors as outlined in the “Inmate Treatment Agreement” form. Only a few inmates 
were recorded as having to end treatment early because of risky behaviors. These 
behaviors included getting a home-made tattoo, exhibiting maniac behavior, and having a 
“dirty” urine sample (testing positive for substance abuse) while on therapy. Several 
inmates also ended treatment early because they were released early from prison and 
therefore could not complete the full course of therapy. 
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Discussion 
 Over the past decade, hepatitis C has become an increasingly common occurrence 
in Massachusetts state correctional facilities.  In a 2003 report by the Metro West Daily 
News, it was estimated that of the 10,000 inmates in the Massachusetts state prison 
system, 3,000 inmates were infected with hepatitis C, accounting for 30% of the male 
population and 40% of the female population (Hillman, 2003).  In an effort to raise 
awareness of this growing epidemic and prevent the spread of hepatitis C within prisons 
and the society where many inmates will be released, hepatitis C treatment has become a 
standard in Massachusetts state correctional facilities.  Since its initiation in 1999, over 
500 inmates have received some form of treatment for an HCV infection.  
 In order to monitor the overall progress of treatment among inmates and assess 
the state of the treatment system in Massachusetts correctional facilities, the HCV 
database was created between 2004 and 2005 as a means to collect and organize 
information regarding the demographics, health, and treatment of inmates.  In 2005, data 
on more than 200 inmates was collected and input into the database.  By the end of this 
project, data on a total of 510 inmates was included in the database.  This updated data 
was used to assess the current state of the treatment system as well as the condition of the 
HCV database.  In terms of the treatment system, conclusions can be drawn from the 
results regarding the general characteristics of inmates who are receiving treatment in 
Massachusetts state correctional facilities and the overall response of inmates to 
treatment since the start of combination therapy in August 2002.  Additional conclusions 
concerning the importance of the HCV database and ways in which it can potentially be 
improved can be made as well.       
Characteristics 
The characteristics of those inmates who were treated for hepatitis C were 
summarized according to five different categories.  To start with, data collected on the 
locations of where inmates started treatment showed that a majority of HCV infected 
inmates were treated at Massachusetts Correctional Institution - Norfolk (78), Souza-
Baranowski Correctional Center (71), and Massachusetts Correctional Institution – 
Shirley (66).  A limited number of inmates received treatment at the Massachusetts 
Alcohol and Substance Abuse Center (2), Old Colony Correctional Center Min (3), 
Bridgewater State Hospital (4), and Massachusetts Correctional Institution - Plymouth 
(4).  Factors which may have contributed to why certain facilities had more inmates 
treated than others include the populations within each facility, the percentage of inmates 
with long enough sentences to qualify for treatment, and the healthcare services and 
resources available at each facility.  For example, with an average daily population of 
1250 inmates, the Massachusetts Correctional Institution at Norfolk is the largest facility 
of its type in the Commonwealth of Massachusetts.  In addition, about eighty-percent of 
the inmate population at the facility is serving time for violent crimes (Massachusetts 
Department of Correction, 2007).  Based on the mere size of the facility and the 
percentage of inmates with long sentence times, it makes sense that Norfolk currently has 
the highest number of inmates who have been treated for HCV.  The facility with the 
second highest frequency of inmates treated was Sousa Baranowski which is the state’s 
newest correctional facility. It is a maximum security prison that offers a full range of 
educational, vocational, and substance abuse programming. The recent establishment of 
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this high security facility as well as the up-to-date healthcare program equally contributes 
to the high percentage of inmates receiving treatment.  Massachusetts Correctional 
Institution-Shirley was the facility with the third highest frequency of inmates who were 
treated for HCV.  This is likely due to the fact that MCI-Shirley Health Services Unit is 
fully staffed seven days a week and 24 hours a day. Healthcare includes services in the 
fields of medicine, dentistry, podiatry, optometry, mental health, psychiatry, psychology, 
and physical therapy. Inmates from all other Department of Correction facilities are 
transported as necessary to MCI-Shirley for these services (Massachusetts Department of 
Correction, 2007).  
 An analysis of the gender of inmates treated in Massachusetts correctional 
facilities showed that 96.5% of inmates treated were male while only  3.5% were female. 
These numbers were very consistent with the actual gender breakdown of the total inmate 
population in Massachusetts facilities. As of January 1, 2006, a survey from the 
Department of Corrections counted 8,802 males and 603 females, representing 94% and 
6% of the inmate population, respectively (Massachusetts Department of Correction: 
Research and Planning Division, 2006).  Besides the overall low percentage of female 
inmates in the Massachusetts facilities, it is important to note that the lower number of 
females receiving treatment can also be attributed to the fact that women often have 
shorter incarcerations, which exclude them from qualifying for the long course of HCV 
therapy (Carol Bova, personal communication).  
 According to the results regarding race/ethnicity of inmates, Caucasians were the 
most frequently treated race, accounting for 62.9% of all treated inmates with valid data. 
Hispanic/Latino and African Americans were nearly tied for the second highest 
race/ethnicity treated with valid percents of 18.5% and 17.7%, respectively. These values 
are only partially reflective of the breakdown of race amongst Massachusetts inmate 
populations.  Between 1997 and 2006, the proportion of Caucasian inmates decreased 
from 48% in 1997 to 44% in 2006.  The percentage of African American similarly 
decreased from 29% in 1997 to 27% in 2006. The percentage of Hispanic inmates was 
the only one to increase from 22% to 27% during this ten-year duration (Massachusetts 
Department of Correction:  Research and Planning Division, 2006). Indeed, it is the 
Caucasian race that accounts for the majority of the inmate population as well as the 
inmates treated for HCV.  However, a large disparity does exist between the high 
percentage of Caucasian inmates treated and the lower percentage of Caucasians within 
the entire inmate population.  Likewise, the inmate population percentages of both 
Hispanics and African Americans are higher than the percentages of Hispanic and 
African American inmates treated for HCV.  This particular data may serve as an 
incentive for management to reexamine treatment selection protocols.  Ideally, knowing 
the number of inmates infected with HCV as well as the breakdown of their ethnicity 
would allow for a more direct display of any treatment selection bias.  Unfortunately, 
information from the database only included information on the inmates who were 
selected for HCV treatment, not for all of the inmates who were infected with this virus, 
including those who did not apply or qualify for treatment, and the reasons for exclusion.    
 An analysis of the age at which inmates started treatment showed that the 
majority of individuals on HCV therapy began treatment in their mid thirties to late 
forties.  The average age of inmates treated was 42.9 while the median was 43 years old. 
These numbers are fairly consistent with the average age of inmates among 
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Massachusetts correctional populations.  According to the Department of Corrections 
survey, the median age of inmates has increased from 33 years in 1997 to 36 years in 
2006.  Similarly, the mean age of inmates has increased from 34 to 38 years during this 
ten year period.  As of 2006, 39% of Massachusetts inmates are ages 40-64 while 31% 
are ages 30-39 (Massachusetts Department of Correction:  Research and Planning 
Division, 2006). Because the ages of those inmates who started treatment ranged from as 
young as 22 to as high as 71 years old, age does not seem to influence HCV treatment 
eligibility. 
 Data collected on HCV genotype showed that the majority of inmates were 
infected with HCV genotype 1 (66.1%).  17.7% of Massachusetts inmates were infected 
with genotype 3, 11.6% of inmates was infected with genotype 2 and only 4.5% of 
inmates had genotype 4.  At 66.1%, this high percentage of inmates infected with HCV 
genotype 1 directly correlates with the high prevalence of genotype 1 in the general 
public.  It is believed that HCV genotype 1 accounts for around 70% of hepatitis C cases 
in the United States (NDDIC, 2006).  
Treatment Outcomes 
 Since August 2002, combination therapy has become the standard form of 
treatment in Massachusetts state correctional facilities.  To summarize the effects of this 
therapy on the outcome of treatment and to identify potential correlations between inmate 
characteristics and the success of treatment, various aspects of the treatment process were 
analyzed.   
 As a historical indicator of a potential HCV infection, baseline ALT levels were 
first analyzed to determine whether or not they accurately correlated with HCV infection 
among inmates.  Alanine aminotransferase, or ALT, is an enzyme produced primarily by 
cells in the liver.  In a normal, healthy individual, ALT levels in the blood tend to range 
between 0 and 40 IU/L; however, this range may vary depending upon the laboratory, 
gender, and biological make-up of an individual.  When cells in the liver are damaged or 
die, ALT levels tend to increase in the blood.  The amount of ALT does not necessarily 
correlate with the amount of damage to the liver, but it does signal that something may be 
wrong with the liver.  In most individuals with hepatitis C, ALT levels are elevated at 
least slightly above normal.  For approximately 30% of these individuals, though, ALT 
levels remain normal (Franciscus and Teeter, 2006).   
 According to the results, baseline ALT levels among inmates ranged from 12 
IU/L to 627 IU/L, with the most frequent levels between 30 IU/L and 79 IU/L.  The 
average ALT level was calculated around 90.26 IU/L; however, this value was slightly 
skewed as a result of the large range in ALT levels among inmates.  The median value of 
68 IU/L was a more accurate representation of the average baseline.  Out of the 302 
inmates represented in Table 6, only 43 inmates (14.2%) had baseline ALT levels in the 
suggested normal range of 0 IU/L to 40 IU/L.  The majority of inmates (86%) had what 
would be considered elevated ALT levels (> 40 IU/L).  Although there were a large 
percentage of inmates with significantly elevated ALT levels, this does not necessarily 
imply that ALT levels correspond with HCV infection and the potential severity of it.  
Many inmates may not have experienced elevated ALT levels at all, but rather, had a 
natural baseline ALT level outside of 40 IU/L.  Studies have also shown that there is a 
poor correlation of ALT levels with disease progression in HCV (Carol Bova, personal 
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communication).  The only accurate conclusion that can be drawn from these results is 
that ALT levels may be a fairly good indicator of an HCV infection, but they are not 
100% accurate, and thus, should not be the only determinant of HCV infection.  
Additional tests, such as liver biopsies and HCV viral loads, should be performed to 
confirm whether or not liver damage is present and/or the HCV virus is present in the 
blood.    
 To evaluate the effects of treatment on baseline ALT levels, the original intent of 
this assessment was to look at changes in ALT levels over time.  At 12 weeks and 24 
weeks into treatment, reductions in ALT levels were expected to occur in direct 
correspondence with reductions in the level of HCV RNA in the blood.  Unfortunately, 
there was not enough data to accurately assess ALT levels beyond the baseline 
measurement.    
 In order to determine the overall effectiveness of treatment among inmates, 
changes in the level of HCV RNA were assessed over time.  Quantitative HCV RNA 
tests are used to measure the level of HCV RNA in the blood of an individual with 
hepatitis C.  These tests do not indicate the severity of the disease or the level of damage 
to the liver, but they do give an exact measurement of the amount of virus in the blood.  
This value is most often referred to as the viral load.  Prior to the start of treatment, 
quantitative tests are used to establish a baseline HCV RNA level (United States 
Department of Veterans Affairs, 2007).  Values greater than 800,000 IU/mL are referred 
to as “high” viral loads, whereas values less than 800,000 IU/mL are referred to as “low” 
viral loads (Franciscus, 2006).  These values are an important indication of whether or 
not patients will have a successful treatment as it is much more difficult to lower the level 
of virus in patients with “high” viral loads than patients with “low” viral loads (United 
States Department of Veterans Affairs, 2007). 
 According to the results of this study, baseline HCV RNA levels varied 
significantly among inmates, ranging from as low as 353 IU/mL to as high as 98,400,000 
IU/mL.  Because of the large range, the mean was calculated at a slightly skewed value of 
2,363,344.53 IU/mL.  It was more reasonable to consider the average baseline HCV RNA 
level around the slightly lower median value of 1,131,740 IU/mL.   Of the inmates 
included in the aforementioned range of baseline HCV RNA levels, the majority had 
what would be considered “high” viral loads.  Based on this data, no accurate conclusions 
can be drawn regarding the severity of HCV infection among inmates with higher HCV 
RNA levels, or whether or not there is any significance in the fact that most inmates had 
“high” viral loads.  This data may, however, serve as an indicator for predicting which 
inmates have a considerably lower chance of responding well to treatment and achieving 
lower levels of virus within their system.  
 To assess the accuracy of this prediction, changes in HCV RNA levels needed to 
be measured over time.  A patient responding well to treatment would achieve a 2-log 
reduction in the level of HCV RNA within 12 weeks.  Unfortunately, there was not 
enough data to assess HCV RNA levels at 12 weeks, 24 weeks, or 48 weeks into 
treatment.  The only factor which could accurately be assessed beyond baseline HCV 
RNA levels was the number of inmates who were able to successfully achieve an 
undetectable viral load.  An undetectable viral load can be defined as the complete 
elimination of HCV RNA in the blood or a level of HCV RNA too low for a quantitative 
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assay to detect.  In either case, an undetectable viral load is reported in labs as < 615 
IU/mL (United States Department of Veterans Affairs, 2007).   
 Results showed that inmates were able to achieve undetectable viral loads (< 615 
IU/mL) as early as 12 weeks into treatment.  Success this early into treatment suggests 
that inmates either had “low” baseline viral loads or responded well to treatment as a 
result of health factors, viral characteristics, or overall good compliance.  Of the 232 
inmates with HCV RNA levels recorded beyond baseline, a total of 178 (76.7%) of them 
were able to achieve an undetectable viral load at least at some point during treatment.   
These numbers are a good indication that treatment was successful among most inmates 
during therapy.  However, a completely successful treatment is measured in terms of a 
sustained virologic response.  For most inmates, HCV RNA levels were not recorded 
beyond the end of therapy.  Consequently, it could not be determined, based on the 
amount of available information, as to whether or not inmates who attained an 
undetectable viral load (< 615 IU/mL) during therapy were able to maintain the same 
level of virus six months later.  
 For those 54 (23.3%) inmates in Table 7 who were unable to achieve an 
undetectable viral load, a lack of success can be accounted for by a number of factors 
including “high” viral loads at the start of treatment, problems associated with the 
medication, or alternative health and viral aspects which may have hindered the inmate’s 
response to treatment.  Particular factors addressed in this project were HCV genotype, 
HIV co-infection, and problems associated with therapy.   
 An analysis was first conducted to determine whether or not HCV genotype had 
any effect on an inmate’s ability to achieve an undetectable viral load (< 615 IU/mL).  
Studies have shown that variations in HCV genotype are an important indication of how a 
patient will respond to interferon therapy.  HCV genotype 1 accounts for approximately 
75% of HCV infections in the United States; however, patients infected with this 
genotype tend to have the most difficulty responding to interferon.  Patients with 
genotypes 2 and 3, on the other hand, account for only 10 to 20 percent of cases in the 
United States and are the most likely to respond to interferon therapy (NDDIC, 2006).  
HCV infections caused by genotype 4 are rarely seen in the United States, but reports 
show that these patients have a similar difficulty in responding to interferon therapy as 
those infected with genotype 1 (Herrine, 2002).  To account for these differences in HCV 
genotype and response to therapy, Massachusetts protocol requires that inmates with 
more problematic genotypes such as 1 and 4 receive a longer period of treatment.  
Whether or not this extension in treatment length actually helps inmates to achieve an 
undetectable viral load was the focus of the analysis.    
 According to the results, there were 217 inmates with a documented HCV 
genotype who also had recorded HCV RNA levels measured beyond the baseline value. 
Of the 149 inmates infected with HCV genotype 1, 106 (71.1%) were able to achieve an 
undetectable viral load (< 615 IU/mL) at some point during treatment.  By comparison, 
62 (91.2%) of the 68 inmates infected with HCV genotypes 2, 3, or 4, were able to 
achieve a similar HCV RNA level during treatment.  Based on the shear number of 
inmates infected with each genotype, it is evident that the trends in HCV infection within 
prisons are accurately representative of the current trends in HCV infection throughout 
the United States.  However, no definitive conclusions can be drawn as to whether or not 
genotype had any effect on the inmate’s abilities to achieve undetectable viral loads (< 
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615 IU/mL).  The percentages suggest that inmates with genotypes 2, 3, and 4 are more 
likely to achieve an undetectable viral load, but there was also a much smaller number of 
inmates infected with these genotypes than those infected with genotype 1.  A larger set 
of inmates infected with genotypes 2, 3, or 4 could have caused a drastic change in the 
percentage that was able to achieve an undetectable viral load (< 615 IU/mL).  All in all, 
there does not appear to be any significant correlation between HCV genotype and the 
success of treatment.  Inmates infected with HCV genotypes 1 or 4 may not respond as 
well to interferon therapy, but alterations in the length of treatment seemed to help the 
majority of inmates achieve an undetectable viral load regardless of their genotype.    
 An additional factor which may account for the unsuccessful outcome of inmates 
in response to treatment is HIV co-infection.  Like hepatitis C, HIV has been a long time 
problem in the prison system.  In a 2003 report by the Metro West Daily News, it was 
estimated that of the 10,000 inmates in the Massachusetts state prison system, 300 
inmates are HIV positive.  Of these inmates, 70% are co-infected with HCV.  This 
number accounts for 10% of the estimated 3,000 inmates infected with hepatitis C 
(Hillman, 2003).  To determine whether or not this percentage was reflected in the 
number of inmates receiving treatment in Massachusetts state correctional facilities, the 
prevalence of HIV co-infection among inmates in the HCV database was assessed.  
Results showed that of the 255 inmates with a documented HIV status, 55 (21.6%) were 
HIV positive.  This value represents a slightly higher percentage of inmates with an 
HCV/HIV co-infection than originally predicted in 2003, but this could be due to a 
number of factors including a lack of available data regarding HIV status, an increase in 
the number of inmates with an HCV/HIV co-infection in the Massachusetts prison 
system, or treatment preference.  Under the Massachusetts protocol, inmates co-infected 
with HIV and HCV are moved to the top of the priority list regardless of when they were 
diagnosed.  This preference, as well as the prevalence of HIV/HCV co-infection in 
Massachusetts state correctional facilities, is what is most likely reflected in the 
percentage of inmates who have an HIV co-infection and have received treatment since 
August 2002.   
 For most patients with an HIV co-infection, the severity of the HCV infection is 
amplified.  Damage to the liver occurs more rapidly, HCV RNA levels in the blood are 
typically higher, and response to treatment is compromised.  In fact, treatment for 
patients co-infected with HIV usually requires a much longer time period (6-12 months) 
and a number of extra precautions not necessarily taken in a normal therapy (CDC, 2005; 
CDC, 2007).  For the inmates with an HIV co-infection in the HCV database, an analysis 
was conducted to determine whether or not HIV co-infection had any effect on an 
inmate’s ability to achieve an undetectable viral load (< 615 IU/mL).  According to the 
results, 165 inmates with a documented HIV status as well as HCV RNA levels recorded 
beyond the baseline value were taken into consideration.  Of the 143 inmates infected 
with only HCV, 81.1% were able to achieve an undetectable viral load (< 615 IU/mL).  
This value is reflective of the results of the previous HCV RNA analysis and further 
confirms the effectiveness of combination therapy towards a successful treatment.  By 
comparison, only 54.5% of the 22 inmates co-infected with HIV were able to achieve a 
similar undetectable viral load (< 615 IU/mL).  These results suggest that an HIV co-
infection at least slightly inhibits an inmate’s ability to achieve an undetectable viral load.  
Out of 22 inmates, there were still a reasonable number of inmates that were able to 
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respond to treatment.  The limited percentage is likely just a reflection of the 
complications caused by HIV co-infection during treatment.  Further data would need to 
be collected in order to make any more definitive conclusions regarding the correlation 
between HIV co-infection and the success of treatment.  However, based solely on these 
results, inmates with an HIV co-infection should not be excluded based on this health 
criterion, alone. 
 Besides HCV genotype and HIV co-infection, a major factor which may have 
contributed to the unsuccessful outcome of inmates in response to treatment is 
complications associated with combination therapy.  In the current treatment system, 
complications are addressed by either a reduction in the dosage of medication or an entire 
discontinuation of treatment.  The solution usually depends upon the nature and severity 
of the problem.   To determine the extent to which these events have occurred since the 
start of combination therapy, treatment interruptions and early discontinuations in 
treatment were each individually assessed.  
 Treatment interruptions can be defined as brief periods of time in which treatment 
is altered in some manner.  These are usually the result of side effects that require 
alterations in the dosage of medication or a movement between correctional facilities. 
Results from this study were based on the 233 inmates who had a documented indication 
of whether or not they had incurred an interruption during treatment.  For 183 (82.1%) of 
these inmates, treatment was administered uninterrupted.  This suggests that the majority 
of inmates either completed treatment successfully or discontinued treatment early as a 
result of a severe problem.  For the remaining 40 (17.9%) inmates, at least one 
interruption was noted at some point during treatment.  Most of these interruptions were 
recorded as changes in the dosage of interferon and/or ribavirin.  Based on these results, 
it is evident that treatment interruptions were an uncommon occurrence for most inmates 
on combination therapy.  There is no clear indication, however, as to whether or not 
inmates who experience interruptions in treatment still have the potential to complete 
treatment successfully or are more likely to cease treatment early.  The only conclusion 
that can be drawn from this information is that for any given hepatitis C treatment, at 
least a few minor interruptions are to be expected.  Medication dosages are not standard 
for every patient and may require slight variations depending upon individual responses.   
 Early discontinuation is normally advised for those inmates who experience more 
severe complications in response to therapy or have an inability to cooperate with 
treatment.  Discontinuation of treatment is defined by a complete cessation in the 
administration of interferon and ribavirin.  Like undetectable viral loads (< 615 IU/mL), 
the number of inmates who stop treatment early is a fair measure of the success of 
combination therapy among inmates.  According to the results of this study, 243 inmates 
had a valid indication of whether or not their treatment was stopped early.  For as many 
as 137 (56.4%) of these inmates, treatment was prematurely terminated.  This was due 
primarily to complications with therapy, which appeared to be the most common reason 
for an inmate’s inability to achieve an undetectable viral load (< 615 IU/mL).  This data 
suggests that although combination therapy is successful among a large percentage of 
inmates, it is evidently just as problematic for a similar proportion of inmates.  Because 
these results are based on a unique set of inmates with valid data, no reliable comparisons 
can be made between these results and those for the percentage of inmates who were able 
to achieve an undetectable viral load.    
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 A qualitative assessment of the reasons for ending treatment early showed that 
termination for most inmates was the result of a specific, individual problem associated 
with therapy.  Broad categories such as poor virologic response, severe side effects, and 
poor compliance with treatment were used to classify each specific problem and 
eliminate the large variation in data.  The original intention of this assessment was to 
qualitatively as well as quantitatively analyze the frequency of each particular problem.  
An understanding of why most inmates are unable to achieve an undetectable viral load 
would not only contribute to the education of other inmates preparing for hepatitis C 
treatment, but it would help healthcare managers to prepare appropriately for any 
potential problem.  Unfortunately, there was a limited amount of data from which 
accurate results or conclusions could be drawn.   
Importance of Database 
A hepatitis C treatment database is valuable tool for the collection, storage, and 
organization of an abundant amount of information.  As a result of the data collected, 
demographic summaries can be periodically performed to characterize those inmates who 
are selected for HCV treatment. Specifically, this report has revealed a slight bias in the 
proportion of race/ethnicity of inmates who have been eligible for treatment. This finding 
was also revealed in the 2005 analysis of Massachusetts inmate demographics (Kelly, 
2005). The managers of the HCV treatment program can use inmate characteristic 
summaries like these as a reference to minimize any intentional or unintentional bias 
which may be a product of the current screening/evaluation protocols and treatment 
qualifications.  
 In addition to inmate characteristics, data assessments regarding treatment 
response and outcomes can also provide direction for the improvement of Massachusetts 
correctional facility protocols for the management of hepatitis C. For example, as 
recently as 2005, the screening process for HCV treatment eligibility was different from 
the currently implemented system.  At that time, elevated ALT levels (> 60 IU/L) were 
needed in order for an inmate to continue with the treatment evaluation process and get a 
liver biopsy (Kelly, 2005). However, it was later realized that many HCV infected 
African Americans would still have normal ALT levels (0-40 IU/L) even if they were 
seriously ill with HCV (Carol Bova, personal communication). As a result of this finding, 
alterations were made to the protocol in order to eliminate ALT eligibility requirements.  
Tests for HCV antibody and HCV RNA levels are now used to determine whether or not 
an inmate qualifies for a liver biopsy and possibly HCV therapy.  This alteration will 
ideally minimize the exclusion of African Americans from treatment in Massachusetts 
correctional facilities.  In this case, summaries of the demographics and outcomes of 
inmates revealed an issue which may have never been exposed or dealt with had their not 
been a system for collecting, organizing, and analyzing treatment data.    
 Beyond the actual process and management of the treatment system, data 
regarding treatment outcomes and response can serve as an important indicator of 
whether or not therapy is successful and whether or not this HCV treatment system is 
worth continuing. For instance, if only a small percentage of inmates were successfully 
responding to therapy, then it may be in the best interest of the Massachusetts 
correctional health system to invest their money and limited budget in the treatment and 
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care of other medical ailments. However, results from this study have shown that HCV 
treatment in Massachusetts correctional facilities has been very effective. 
 For inmates who are unable to respond successfully to treatment, data collection 
can only help to further improve healthcare facilities in prisons.  Information regarding 
treatment complications such as poor response to therapy and medication side effects will 
keep the staff informed of common medical problems associated with HCV treatment and 
facilitate them in being more prepared and better equipped to help patients cope with 
difficult symptoms while on treatment.  This information may also be used to help 
educate inmates on what to expect during treatment prior to the start of therapy.  
   
Recommendations 
 One of the primary constraints of this project was the limited amount of available 
data.  For all inmates, information was extracted directly from individual hepatitis C 
worksheets.  Any areas that were left blank or had no indication of an unknown or non-
applicable variable were correspondingly left blank in the database.  These blank spaces 
were accumulatively referred to by SPSS as “missing system” data.   
 For most inmates, data was missing in at least one or two different fields.  
However, for an even larger proportion of inmates, data was missing in nearly every 
field.  Variables such as sustained viral load measures and the inmate’s history of 
substance abuse and health conditions were recorded for less than half the inmates 
included in the database.  This factor not only affected the accuracy of the analyses 
performed for this project, but also limited the number of fields that could be assessed.  In 
order to ensure the quality and reliability of the database as well the accuracy of 
statistical analyses based on information in the database, improvements must be made in 
the collection and recording of data.  
 One major problem that accounted for the majority of “missing system” data was 
the irregularity in data recording on the hepatitis C worksheets.  Some HIV/Hepatitis C 
case managers indicated unknown and non-applicable fields on the worksheet with an 
N/A, an Ø, or a brief note.  Other case managers simply left the areas blank with no 
indication as to whether or not information was unknown, missing, or not applicable.  As 
a standard procedure for data collection, these blank fields were left blank in the 
database, but whether or not data was actually missing from these fields was unclear.   
 In order to avoid confusion and future issues like these, it would be ideal for all 
case managers to follow a standard protocol.  This does not mean that data needs to be 
recorded in exactly the same way for every inmate, but it should be clear in every area of 
the hepatitis C worksheet as to whether or not data is known, unknown, missing, or not 
applicable.  Regularity among the hepatitis C worksheets would potentially help to 
eliminate a large proportion of “missing system” data in the database, particularly in 
areas such as health conditions, mental health conditions, and history of substance abuse 
and alcohol abuse.    
 The only other major problem that accounted for “missing system” data and 
altered the outcome of many of the data analyses conducted for this project was the 
extent of missing lab results.  For some inmates, lab results were extensive.  Values were 
recorded in the hepatitis C worksheet for nearly every lab prior to the start of treatment 
and during treatment.  For the majority of inmates, however, lab results were nearly 
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nonexistent.  Baseline levels were recorded for the required labs, but few values were 
recorded beyond the start of treatment.  In particular, HCV RNA levels 6 months 
following treatment were missing for nearly every inmate.  Less than a quarter of them 
had any note of a sustained virologic response.  The consequences of this missing data 
were noted primarily during this project in the inability to monitor treatment progress and 
success among inmates. 
 As a suggestion to improve the collection of lab data, specifically during and 
following treatment, the correctional health system may want to consider implementing a 
stricter data collection system.  Any inmate who is receiving treatment for hepatitis C 
should be closely monitored both during treatment and six months following treatment.  
Case managers or other health care personnel within the individual facilities should help 
to ensure during this time that necessary labs are performed at the required times.  Lab 
results recorded immediately following the lab will help to guarantee that data is not 
missing from the hepatitis C worksheet.   
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